Return on Tangible Equity: The amount of net income returned as a percentage of shareholders equity, after subtracting intangible assets, goodwill and preferred equity. Calculated as: Income from Continuing Operations / Tangible Shareholders Equity
Mineralys Therapeutics, Inc. (MLYS) had Return on Tangible Equity of -12.36% for the most recently reported fiscal quarter, ending 2025-03-31.
| Income Statement Financials | |
-- |
|
$-42.21M |
|
-- |
|
-- |
|
$44.45M |
|
$-44.45M |
|
$2.24M |
|
$-42.21M |
|
$-42.21M |
|
$-42.21M |
|
$-42.21M |
|
$-42.21M |
|
$-42.21M |
|
$-44.45M |
|
$-44.43M |
|
53.16M |
|
53.16M |
|
$-0.79 |
|
$-0.79 |
|
| Balance Sheet Financials | |
$354.51M |
|
$0.04M |
|
$0.43M |
|
$354.94M |
|
$13.39M |
|
-- |
|
-- |
|
$13.39M |
|
$341.56M |
|
$341.56M |
|
$341.56M |
|
64.88M |
|
| Cash Flow Statement Financials | |
$-45.49M |
|
$-92.88M |
|
$189.28M |
|
$114.09M |
|
$165.01M |
|
$50.92M |
|
$3.65M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
26.48 |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
$-45.49M |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-12.36% |
|
|
Return on Tangible Equity |
-12.36% |
-11.89% |
|
-12.36% |
|
$5.26 |
|
$-0.86 |
|
$-0.86 |
|